Evidence map›Paper›PMID 34356931›Full record

ArticleJournal of fungi (Basel, Switzerland)2021

Antifungal Drug Susceptibility and Genetic Characterization of Fungi Recovered from COVID-19 Patients.

Milena Kordalewska, Kevin D Guerrero, Rocio Garcia-Rubio, Cristina Jiménez-Ortigosa, José R Mediavilla, Marcus H Cunningham, Frank Hollis, Tao Hong, Kar Fai Chow, Barry N Kreiswirth and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of fungi (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Milena KordalewskaCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA.
Kevin D GuerreroCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA.
Rocio Garcia-RubioCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA.ORCID 0000-0003-4610-2996
Cristina Jiménez-OrtigosaCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA.
José R MediavillaCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA.
Marcus H CunninghamCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA.
Frank HollisHackensack University Medical Center, Hackensack, NJ 07601, USA.
Tao HongHackensack University Medical Center, Hackensack, NJ 07601, USA.
Kar Fai ChowHackensack University Medical Center, Hackensack, NJ 07601, USA.
Barry N KreiswirthCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA.
David S PerlinCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA.
Hackensack Meridian Health · USHackensack University Medical Center · US

Funding

CDI COVID-19 Pilot Research GrantCDI COVID-19 ResponseHMH Foundation DSPMerck's Investigator Studies Program 60453
6 · The paper itself

Abstract

Fungal infections are common complications of respiratory viral infections and are associated with the increased need for intensive care and elevated mortality. Data regarding microbiological and molecular characteristics of such infections in COVID-19 patients are scarce. Here, we performed a comprehensive analysis, including species identification, antifungal susceptibility testing, molecular resistance determinants analysis, typing, and retrospective clinical data review, of fungal isolates recovered from 19 COVID-19 patients, who were hospitalized at the Hackensack University Medical Center (HUMC) in Hackensack, New Jersey, USA, in the initial phase of the pandemic from April-May 2020. In total, 17

Indexed as

antifungal susceptibilityaspergillosisAspergillus fumigatusCandida albicansCandida parapsilosisCandida pneumoniacandidiasisCOVID-19COVID-19-associated candidemiasecondary infections

Identifiers

PMID34356931
PMCPMC8306261
OpenAlexW3182442173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.